ibio inc (IBIO) Key Developments
iBio, Inc. Presents at 5th LD Micro Invitational Conference, Jun-01-2015 11:30 AM
May 23 15
iBio, Inc. Presents at 5th LD Micro Invitational Conference, Jun-01-2015 11:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States.
iBio, Inc. Arranges Production of iBio CFB03 for Clinical Development with Caliber Biotherapeutics
Apr 27 15
iBio Inc. has engaged Caliber Biotherapeutics LLC to scale-up and produce materials for clinical development of the first of iBio's proprietary anti-fibrosis products, IBIO-CFB03. Caliber's production will be used for IND-enabling toxicology studies and initial human clinical trials of IBIO-CFB03. The expansion in 2014 of iBio's exclusive technology collaboration with Novici Biotech LLC broadened iBio's fibrosis therapeutics program through a combination of the strengths of iBio's proprietary iBioLaunch(TM) platform technology with Novici's patented optimization technology. iBio then engaged CBR International Corporation for strategic regulatory and clinical services and assembled a Clinical Advisory Board of internationally recognized experts in fibrotic diseases to assist the company in clinical product development and human trial design.
iBio, Inc. announced delayed 10-Q filing
Feb 17 15
On 02/17/2015, iBio, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Levi & Korsinsky Announces Class Action Lawsuit iBio, Inc
Dec 1 14
Levi & Korsinsky announced that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. securities between October 13, 2014 and October 23, 2014. The complaint alleges that during the class period, the company issued materially false and misleading statements to investors by wrongfully suggesting that the company's launch platform patents and related proprietary technology would be licensed by the makers of the experimental Ebola drug, ZMapp. The complaint alleges that when the true facts were revealed, the price of the company's stock fell significantly, damaging investors.
iBio, Inc., Annual General Meeting, Dec 10, 2014
Nov 12 14
iBio, Inc., Annual General Meeting, Dec 10, 2014., at 10:00 US Eastern Standard Time. Location: Omni Berkshire Place Hotel, 21 East 52 Street. Agenda: To elect two directors each to serve as Class III directors for a three year term expiring at the 2017 annual meeting of stockholders or until successors have been duly elected and qualified; to ratify the appointment of CohnReznick LLP as the company's independent registered public accounting firm for the fiscal year ending June 30, 2015; to approve an advisory vote on executive compensation; and to transact any other business properly brought before the annual meeting.